The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population

The COMPASS trial assessed the impact of adding low dose rivaroxaban to aspirin in selected patients (pts). After an acute myocardial infarction (MI), when dual antiplatelet treatment is no longer needed, patients might be eligible for aspirin/rivaroxaban co-therapy. The characteristics and risks of such a population are unclear.

Source: International Journal of Cardiology - December 3, 2018 Category: Cardiology Authors: Fran çois Schiele, Etienne Puymirat, Jean Ferrières, Tabassome Simon, Keith A.A. Fox, John Eikelboom, Nicolas Danchin, FAST-MI investigators Source Type: research